Pamuk, GETurgut, BVurul, ÖDemir, MTek, MAltaner, S2024-06-122024-06-1220030141-9854https://doi.org/10.1046/j.1365-2257.2003.00534.xhttps://hdl.handle.net/20.500.14551/21676Hydroxyurea is a ribonucleotide diphosphate reductase inhibitor used in the treatment of patients with myeloproliferative disorders. Hydroxyurea has some dermatological side-effects. It has recently been recognized that hydroxyurea can induce squamous cell and basal cell carcinomas of skin. We present the case of an elderly man with chronic myeloid leukaemia who was treated with hydroxyurea for 4 years, with good control of his disease. However, in addition to the appearance of various skin lesions and cutaneous squamous cell carcinoma after 3 years of therapy, he was found to have a metastatic squamous cell carcinoma after 4 years. Hydroxyurea was discontinued, and he underwent surgery and radiotherapy. The patient subsequently died of ventricular fibrillation. We present this case to draw attention to the association between hydroxyurea and secondary skin cancers and to emphasize the need for dermatological examination before and during the course of hydroxyurea therapy.en10.1046/j.1365-2257.2003.00534.xinfo:eu-repo/semantics/closedAccessHydroxyureaChronic Myeloid LeukaemiaSquamous Cell CarcinomaArticle255329331Q4WOS:0001853450000112-s2.0-014152846112974726N/A